The Montreal Heart Institute, in Montreal, Quebec, is a specialty hospital dedicated to the development of cardiology, which is affiliated with the Université de Montréal.

There are 153 beds in Montreal Heart Institute.

During the past decade, Montreal Heart Institute conducted 125 clinical trials. In the 10-year time frame, 125 clinical trials started and 54 clinical trials were completed, i.e. on average, 43.2% percent of trials that started reached the finish line to date. In the past 5 years, 49 clinical trials started and 26 clinical trials were completed. i.e. 53.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Montreal Heart Institute" #1 sponsor was "Montreal Heart Institute" with 55 trials, followed by "Abbott Medical Devices" with 14 trials sponsored, "Ottawa Heart Institute Research Corporation" with 13 trials sponsored, "Medtronic Cardiac Rhythm and Heart Failure" with 9 trials sponsored and "Icahn School of Medicine at Mount Sinai" with 9 trials sponsored. Other sponsors include 145 different institutions and companies that sponsored additional 112 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Montreal Heart Institute" #1 collaborator was "Canadian Institutes of Health Research (CIHR)" with 32 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 21 trials as a collaborator, "Montreal Heart Institute" with 12 trials as a collaborator, "Medtronic" with 7 trials as a collaborator and "National Institute of Neurological Disorders and Stroke (NINDS)" with 6 trials as a collaborator. Other collaborators include 189 different institutions and companies that were collaborators in the rest 149 trials.

According to Clinical.Site data, the most researched conditions in "Montreal Heart Institute" are "Heart Failure" (33 trials), "Atrial Fibrillation" (28 trials), "Coronary Artery Disease" (24 trials), "Myocardial Infarction" (12 trials) and "Heart Diseases" (8 trials). Many other conditions were trialed in "Montreal Heart Institute" in a lesser frequency.

Most popular intervention types in "Montreal Heart Institute" are "Drug" (109 trials), "Device" (73 trials), "Procedure" (36 trials), "Other" (34 trials) and "Behavioral" (9 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (34 trials), "placebo" (5 trials), "Apixaban" (4 trials), "Colchicine" (4 trials) and "Ranolazine" (4 trials). Other intervention names were less common.

The vast majority of trials in "Montreal Heart Institute" are 248 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are 67 active trials in "Montreal Heart Institute". 3 are not yet recruiting, 38 are recruiting, 21 are Active, not recruiting, and 5 are Enrolling by invitation. In total, there were 147 completed trials in Montreal Heart Institute, undefined suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in Montreal Heart Institute, 4 "Phase 1" clinical trials were conducted, 39 "Phase 2" clinical trials and 68 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 21 trials, and there were also 76 trials that are defined as “Not Applicable".